SCHEMBL5167067

SCHEMBL5167067

COC(=O)c1ccc(N2C(=O)c3cccc4cc([N+](=O)[O-])cc(c34)C2=O)cc1

nearest known ligand 0.64

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CA9 Q16790 5/20 0.64
CA12 O43570 4/20 0.64
CA1 P00915 3/20 0.64
CA2 P00918 3/20 0.64
CLTC Q00610 2/20 0.59
KMT2A Q03164 5/20 0.57
MEN1 O00255 4/20 0.57
POLB P06746 4/20 0.57
L3MBTL1 Q9Y468 3/20 0.57
CASP6 P55212 1/20 0.57
TDP1 Q9NUW8 1/20 0.56
FTO Q9C0B1 2/20 0.53
NTRK1 P04629 1/20 0.53
NGFR P08138 1/20 0.53
BRD1 O95696 1/20 0.52
TAF1 P21675 1/20 0.52
BRPF1 P55201 1/20 0.52
PABPC1 P11940 2/20 0.51
RXFP1 Q9HBX9 1/20 0.50
MAPT P10636 2/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4235535 0.87 CLTC (0.73) CA9CA12CA1CA2CLTC
SCHEMBL14159191 0.83 CA12 (0.73) CA9CA12CA1CA2CLTC
SCHEMBL717142 0.81 CA12 (0.74) CA9CA12CA1CA2CLTC
SCHEMBL5161227 0.80 MEN1 (0.75) CA9CA12CA1CA2CLTC
SCHEMBL5533314 0.80 CA12 (0.79) CA9CA12CA1CA2CLTC
SCHEMBL14533642 0.80 CA12 (0.69) CA9CA12CA1CA2CLTC
SCHEMBL5162915 0.80 CA12 (0.65) CA9CA12CA1CA2CLTC
SCHEMBL4235316 0.79 MEN1 (0.89) CA9CA12CA1CA2CLTC
SCHEMBL14159218 0.79 CA12 (0.51) CA9CA12CA1CA2CLTC
SCHEMBL5150416 0.78 MEN1 (0.70) CA9CA1CA2KMT2AMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070123514-A1 Methods of modulating neurotrophin-mediated activity PAINCEPTOR PHARMA CORPORATION (CA) 2007-05-31 US claimed
WO-2007030939-A2 METHODS OF MODULATING NEUROTROPHIN-MEDIATED ACTIVITY PAINCEPTOR PHARMA CORPORATION (CA) 2007-03-22 WO claimed
US-20070123514-A1 Methods of modulating neurotrophin-mediated activity PAINCEPTOR PHARMA CORPORATION (CA) 2007-05-31 US disclosed
US-20070123514-A1 Methods of modulating neurotrophin-mediated activity PAINCEPTOR PHARMA CORPORATION (CA) 2007-05-31 US disclosed
US-20070123514-A1 Methods of modulating neurotrophin-mediated activity PAINCEPTOR PHARMA CORPORATION (CA) 2007-05-31 US disclosed
WO-2007030939-A2 METHODS OF MODULATING NEUROTROPHIN-MEDIATED ACTIVITY PAINCEPTOR PHARMA CORPORATION (CA) 2007-03-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070123514-A1 Methods of modulating neurotrophin-mediated activity NGF, BDNF, NTRK2 CA9 3754/4885CA12 1700/4885CA1 847/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.